Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Behavioral and Pharmacological Treatments to Enhance Weight Outcomes After Bariatric Surgery
NCT05157698Phase 3Completed
- Sponsor
- Yale University
- Start
- Jan 2022
- Primary completion
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of naltrexone, bupropion in obesity, sponsored by Yale University. Started Jan 2022; status: completed.
02
Drugs
naltrexonebupropion
03
Conditions
obesity
Beyond the preview
Go deeper on NCT05157698.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05157698.